Allogeneic islet isolation: Methods to improve islet cell transplantation with new technologies in organ transplant retrieval and isolation techniques

Balamurugan, Appakalai N.; Samaga, Krishna Kumar; Narayanan, Siddharth; Kodipad, Ahad Ahmed; Mokshagundam, Sri Prakash L.; Nathan, Jaimie D.

doi:10.1016/b978-0-12-824011-3.00008-4

Cited by 1 publication

(3 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic islets are highly metabolic cells, and the many stress factors and hypoxic episodes experienced during islet isolation or the process of creating new human islets from stem cells, and as a result of transplant procedures are challenges for islet recovery and function. [27][28][29][30] Conventionally, islets have been implanted in the hepatic portal vein with eventual embolization in the liver. 31 Although this method has been well characterized, only 30% of the original islet mass remains viable.…”

Section: Identifying Clinical Outcomesmentioning

confidence: 99%

“…ICT procurement and islet isolation procedures and their effects on patient outcomes remain important topics in ICT development. Pancreatic islets are highly metabolic cells, and the many stress factors and hypoxic episodes experienced during islet isolation or the process of creating new human islets from stem cells, and as a result of transplant procedures are challenges for islet recovery and function 27–30 …”

Section: Building a Target Product Profile For Ictmentioning

confidence: 99%

Section: Building a Target Product Profile For Ictmentioning

confidence: 99%

See 2 more Smart Citations

Combinatorial islet protective therapeutic approaches in β‐cell transplantation: Rationally designed solutions using a target product profile

Brauns

Sluder

et al. 2023

FASEB BioAdvances

View full text Add to dashboard Cite

While progress has been made in the development of islet cell transplantation (ICT) as a viable alternative to the use of exogenous insulin therapy in the treatment of type 1 diabetes, it has not yet achieved its full potential in clinical studies. Ideally, ICT would enable lifelong maintenance of euglycemia without the need for exogenous insulin, blood glucose monitoring or systemic immune suppression. To achieve such an optimal result, therapeutic approaches should simultaneously promote long‐term islet viability, functionality, and localized immune protection. In practice, however, these factors are typically tackled individually. Furthermore, while the requirements of optimal ICT are implicitly acknowledged across numerous publications, the literature contains few comprehensive articulations of the target product profile (TPP) for an optimal ICT product, including key characteristics of safety and efficacy. This review aims to provide a novel TPP for ICT and presents promising tried and untried combinatorial approaches that could be used to achieve the target product profile. We also highlight regulatory barriers to the development and adoption of ICT, particularly in the United States, where ICT is only approved for use in academic clinical trials and is not reimbursed by insurance carriers. Overall, this review argues that the clear definition of a TPP in addition to the use of combinatorial approaches could help to overcome the clinical barriers to the widespread adoption of ICT for the treatment of type 1 diabetes.

show abstract